Hemorrhagic Disease

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Hemorrhagic Disease

MalaCards integrated aliases for Hemorrhagic Disease:

Name: Hemorrhagic Disease 12 15
Hemorrhagic Disorders 43 71
Hemorrhagic Diathesis 12
Hemorrhagic Diseases 54
Bleeding Tendency 71


External Ids:

Disease Ontology 12 DOID:2213
ICD9CM 34 287.9
MeSH 43 D006474
ICD10 32 D68.3 D69.9
UMLS 71 C0019087 C1458140

Summaries for Hemorrhagic Disease

MalaCards based summary : Hemorrhagic Disease, also known as hemorrhagic disorders, is related to vitamin k deficiency bleeding and von willebrand disease, type 2, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Hemorrhagic Disease is F11 (Coagulation Factor XI), and among its related pathways/superpathways are Collagen chain trimerization and Response to elevated platelet cytosolic Ca2+. The drugs Tinzaparin and Nadroparin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Hemorrhagic Disease

Diseases in the Hemorrhagic Disease family:

Rare Hemorrhagic Disorder Due to an Acquired Coagulation Factor Defect Hemorrhagic Disease Due to Alpha-1-Antitrypsin Pittsburgh Mutation
Rare Hemorrhagic Disorder Due to a Platelet Anomaly Rare Hemorrhagic Disorder Due to a Coagulation Factors Defect
Rare Hemorrhagic Disorder Rare Hemorrhagic Disorder Due to an Acquired Platelet Anomaly
Rare Hemorrhagic Disorder Due to a Constitutional Thrombocytopenia Rare Hemorrhagic Disorder Due to a Qualitative Platelet Defect
Rare Hemorrhagic Disorder Due to a Constitutional Platelet Anomaly Rare Hemorrhagic Disorder Due to a Constitutional Coagulation Factors Defect

Diseases related to Hemorrhagic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 461)
# Related Disease Score Top Affiliating Genes
1 vitamin k deficiency bleeding 32.5 SERPINC1 F9 F8 F7 F3 F2
2 von willebrand disease, type 2 32.1 VWF GP1BA F8
3 von willebrand disease, type 3 32.1 VWF GP1BA F8
4 alpha-2-plasmin inhibitor deficiency 31.7 SERPINF2 SERPINC1 F8 F7 F3 F2
5 factor x deficiency 31.6 F9 F7 F5 F3 F2 F11
6 von willebrand disease, type 1 31.6 VWF GP6 GP1BA F8 F3 F2
7 factor vii deficiency 31.6 SERPINC1 F9 F8 F7 F3 F2
8 factor xi deficiency 31.3 VWF THBD SERPINC1 F9 F8 F7
9 thrombophilia due to activated protein c resistance 31.0 VWF THBD SERPINF2 SERPINE1 SERPINC1 PLAT
10 hemophilia 30.9 F9 F8 F7
11 polycythemia vera 30.8 VWF THBD F5 F2
12 thrombocytopenic purpura, autoimmune 30.7 GP6 GP1BA F8
13 leech infestation 30.6 SERPINC1 F3 F10
14 placental abruption 30.5 THBD SERPINC1 F5 F2
15 qualitative platelet defect 30.5 VWF F7 F3 F2
16 hemolytic anemia 30.3 VWF THBD F3 F2
17 acquired thrombocytopenia 30.3 GP1BA F11
18 factor xii deficiency 30.3 VWF SERPINC1 F9 F5 F3 F11
19 compartment syndrome 30.3 SERPINC1 F8 F7 F3 F2
20 alpha-1-antitrypsin deficiency 30.2 SERPINE1 SERPINC1 SERPINA1 F2
21 bilirubin metabolic disorder 30.2 F9 F3 F2
22 placental insufficiency 30.1 VWF SERPINE1 SERPINC1 F3 F2
23 hemopericardium 30.0 F3 F2
24 hypothyroidism 29.9 VWF SERPINE1 F9 F8 F3 F2
25 acquired von willebrand syndrome 29.9 VWF GP1BA F9 F8 F7 F3
26 acute promyelocytic leukemia 29.9 VWF THBD SERPINF2 SERPINE1 SERPINC1 PLAT
27 bombay phenotype 29.9 VWF FUT2
28 thrombasthenia 29.9 GP1BA F5 F3 F2
29 hemophilia b 29.8 VWF SERPINC1 SERPINA1 F9 F8 F7
30 purpura 29.8 VWF THBD SERPINC1 GP1BA F3 F2
31 thrombocytosis 29.8 VWF SERPINC1 F3 F2
32 eclampsia 29.8 THBD SERPINE1 SERPINC1 F2
33 acquired hemophilia a 29.8 F9 F8 F5 F3 F11
34 hemophilia a 29.8 VWF F9 F8 F7 F3
35 active peptic ulcer disease 29.7 VWF P2RY12 F7 F3 F2
36 acquired hemophilia 29.7 F9 F8 F5 F3 F11 F10
37 liver cirrhosis 29.6 SERPINF2 SERPINC1 SERPINA1 F3 F2
38 von willebrand's disease 29.5 VWF PLAT P2RY12 GP6 GP1BA F9
39 blood platelet disease 29.5 VWF SERPINC1 GP6 GP1BA F8 F7
40 heart disease 29.5 VWF SERPINE1 SERPINC1 PLAT F8 F7
41 afibrinogenemia, congenital 29.5 VWF SERPINF2 SERPINE1 SERPINC1 PLAT F8
42 arteriosclerosis 29.5 THBD SERPINE1 SERPINC1 GP1BA F3
43 factor v deficiency 29.5 VWF F9 F8 F7 F5 F3
44 thrombotic thrombocytopenic purpura 29.4 VWF THBD SERPINF2 SERPINC1 PLAT F3
45 varicose veins 29.4 VWF THBD SERPINC1 PLAT F5 F2
46 hemarthrosis 29.3 VWF F9 F8 F7 F3 F2
47 prothrombin deficiency 29.3 SERPINC1 F9 F8 F7 F3 F2
48 essential thrombocythemia 29.2 VWF THBD SERPINE1 SERPINC1 GP1BA F3
49 thrombophilia due to thrombin defect 29.1 THBD SERPINE1 SERPINC1 PLAT F8 F5
50 cerebrovascular disease 29.0 VWF THBD SERPINE1 PLAT GP1BA F8

Comorbidity relations with Hemorrhagic Disease via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease

Graphical network of the top 20 diseases related to Hemorrhagic Disease:

Diseases related to Hemorrhagic Disease

Symptoms & Phenotypes for Hemorrhagic Disease

UMLS symptoms related to Hemorrhagic Disease:

edema, chest pain, angina pectoris, abnormal bruising

GenomeRNAi Phenotypes related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.44 F10 F13A1 F5 F7 FUT2 SERPINE1
2 Decreased viability GR00381-A-1 9.44 PLAT SERPINF2
3 Decreased viability GR00381-A-2 9.44 SERPINF2
4 Decreased viability GR00386-A-1 9.44 F8 GP1BA
5 Decreased viability GR00402-S-2 9.44 F11 P2RY12

MGI Mouse Phenotypes related to Hemorrhagic Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 F10 F11 F13A1 F2 F3 F5
2 cardiovascular system MP:0005385 10.22 F10 F11 F13A1 F2 F3 F5
3 hematopoietic system MP:0005397 10.21 F11 F13A1 F2 F3 F8 F9
4 mortality/aging MP:0010768 10.09 F10 F11 F13A1 F2 F3 F5
5 immune system MP:0005387 10.03 F11 F2 F3 F8 F9 FUT2
6 reproductive system MP:0005389 9.61 F10 F13A1 F2 F8 FUT2 GP6
7 respiratory system MP:0005388 9.17 F11 F13A1 F2 F3 PLAT SERPINE1

Drugs & Therapeutics for Hemorrhagic Disease

Drugs for Hemorrhagic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
Nadroparin Approved, Investigational Phase 4
Dalteparin Approved Phase 4 9005-49-6
Abciximab Approved Phase 4 143653-53-6
Tirofiban Approved Phase 4 144494-65-5 60947
Ticagrelor Approved Phase 4 274693-27-5 9871419
Remifentanil Approved Phase 4 132875-61-7 60815
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
Tenecteplase Approved Phase 4 191588-94-0
15 Indobufen Investigational Phase 4 63610-08-2
Chitosan Experimental Phase 4 9012-76-4 71853
17 Plasminogen Phase 4
18 Antidotes Phase 4
19 Charcoal Phase 4
20 Tissue Plasminogen Activator Phase 4
21 Heparin, Low-Molecular-Weight Phase 4
22 Hemostatics Phase 4
23 Narcotics Phase 4
24 Analgesics, Opioid Phase 4
25 Chelating Agents Phase 4
26 Dialysis Solutions Phase 4
27 Fibrinolytic Agents Phase 4
28 Platelet Aggregation Inhibitors Phase 4
29 Purinergic P2Y Receptor Antagonists Phase 4
30 Neurotransmitter Agents Phase 4
31 calcium heparin Phase 4
Diclofenac Approved, Vet_approved Phase 2, Phase 3 15307-86-5 3033
Tranexamic Acid Approved Phase 3 1197-18-8 5526
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
Turmeric Approved, Experimental, Investigational Phase 3
Vorinostat Approved, Investigational Phase 3 149647-78-9 5311
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
Sodium citrate Approved, Investigational Phase 3 68-04-2
Levobupivacaine Approved, Investigational Phase 3 27262-47-1 92253
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
Polidocanol Approved Phase 2, Phase 3 9002-92-0
Alprostadil Approved, Investigational Phase 2, Phase 3 745-65-3 149351 5280723
Ketorolac Approved Phase 2, Phase 3 66635-83-4, 74103-06-3 3826
Mercaptopurine Approved Phase 3 50-44-2 667490
Danazol Approved Phase 3 17230-88-5 28417
Hydroxyurea Approved Phase 3 127-07-1 3657
Melphalan Approved Phase 3 148-82-3 460612 4053
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 147)
# Name Status NCT ID Phase Drugs
1 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
2 the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy Unknown status NCT03230851 Phase 4 aspirin 100mg/d therapy;aspirin 100mg/2d therapy;aspirin 100mg/3d therapy;aspirin 50mg bid therapy;aspirin 75mg/d therapy;aspirin 50mg/d therapy;indobufen 100mg bid therapy
3 Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants Unknown status NCT02969746 Phase 4 Activated Charcoal
4 Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized,Multi-Center,Controlled Trial Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
5 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
6 Conventional Versus Point-of-care Based Coagulation Management in Cardiac Surgery Patients Suffering From Increased Bleeding Tendency - a Prospective and Randomized Study Completed NCT00997841 Phase 4
7 FATA: Comparison Between Tirofiban and Abciximab in Facilitated Angioplasty With Stent Implantation: Randomized Multicentre Study Completed NCT00383136 Phase 4 tirofiban high-bolus dose regimen;Abciximab
8 Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction Completed NCT04369534 Phase 4 Clopidogrel;Ticagrelor
9 Can Opioid-induced Hyperalgesia be Prevented by Gradual Dose Reduction vs. Abrupt Withdrawal of Remifentanil? Completed NCT01702389 Phase 4 Remifentanil
10 Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial Completed NCT01269112 Phase 4
11 USF Hemostasis: USage of HemCon for Femoral Hemostasis After Percutaneous Completed NCT00716365 Phase 4
12 Post-marketing Investigation (PMI) to Assess Safety and Efficacy of Jivi (BAY 94-9027) Treatment in Participants With Hemophilia A Recruiting NCT04085458 Phase 4 Damoctocog alfa pegol (Jivi, BAY94-9027)
13 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
14 CT-guided Ganglion Impar Block for Management of Phantom Rectal Pain Syndrome Recruiting NCT03694639 Phase 4
15 TRIANA: A Randomized Trial to Compare the Efficay and Safety of Thrombolysis With Primary Angioplasty as Initial Reperfusion Therapy in Older Patients (>= 75 Years Old) With Acute Myocardial Infarction Terminated NCT00257309 Phase 4 Tenecteplase + UFH (+ clopidogrel, since 01/97)
16 Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy? Terminated NCT00334204 Phase 4
17 The Influence of High-Dose Aprotinin and Tranexamic Acid on Bleeding Tendency and Allogeneic Blood Transfusion in Patients Undergoing Primary Aortic Valve Replacement or Coronary Artery Revascularization Unknown status NCT00396760 Phase 3 aprotinin or tranexamic acid
18 Comparative Study Between the Effect of Diclofanic and Ketorolac in Post Tonsillectomy Pain Management Unknown status NCT03178539 Phase 2, Phase 3 diclofenac;ketorolac
19 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
20 Effect of Ascorbic Acid Administration on Intraoperative Blood Loss and Wound Healing in Total Abdominal Hysterectomy Completed NCT03965637 Phase 3 vitamin C
21 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies Completed NCT01178294 Phase 2, Phase 3
22 Prospective Study Comparing EUS Guided Biliary Drainage and ERCP With Stent Placement for Malignant Biliary Obstruction Completed NCT01421836 Phase 2, Phase 3
23 Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Efficacy and Safety of Topical Application of Tranexamic Acid for Saving Blood Losses in Patients Subjected to Prosthetic Knee Surgery Completed NCT03386656 Phase 3 Amchafibrin
24 Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Gynaecologic Surgery With Expected Need of Post-operative Opioids Completed NCT00373464 Phase 3 etoricoxib
25 A Randomized, Double Blind, Placebo-controlled Crossover Study on the Effect of Commonly Used Herbal Products on Platelet Function and Coagulation Profile of Healthy Volunteers Completed NCT02008981 Phase 3 Curcuma longa;Angelica sinensis;Siwu Tang;Aspirin
26 Cooperative Study of Factor VIII Inhibitors Completed NCT00000582 Phase 3 factor ix
27 An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma Completed NCT00773747 Phase 3 vorinostat;bortezomib;placebo to vorinostat
28 Enteric-coated Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients (the APREMEC Trial): a Large-scale Multicenter Randomized Double-blind Placebo-controlled Trial Recruiting NCT02607072 Phase 3 Acetylsalicylic acid (ASA)/aspirin 200 mg daily;Acetylsalicylic acid (ASA)/aspirin 100 mg daily;Placebo
29 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4) Recruiting NCT04275323 Phase 3
30 A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA) Recruiting NCT03165734 Phase 3 Pacritinib;Physician's Choice medications
31 Safety and Efficacy of Magnesium Sulphate as an Adjuvant to Levobupivacaine in Ultra-sound Guided Transversus Abdominis Plan Block in Pediatric Abdominal Cancer Surgery Recruiting NCT03979599 Phase 3 magnesium sulphate& levobupivacaine;Levobupivacaine
32 Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study Recruiting NCT04188171 Phase 2, Phase 3
33 ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX Active, not recruiting NCT03417245 Phase 3 fitusiran;factor VIII or factor IX
34 ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX Active, not recruiting NCT03417102 Phase 3 fitusiran;Bypassing agents
35 Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT Active, not recruiting NCT02338440 Phase 2, Phase 3 lipoprostaglandin E1
36 Phase 3 Study To Evaluate Efficacy/Safety of Valoctocogene Roxaparvovec an AAV Vector-Mediated Gene Transfer of hFVIII at a Dose of 4E13vg/kg in Hemophilia A Patients With Residual FVIII Levels ≤1IU/dL Receiving Prophylactic FVIII Infusions Active, not recruiting NCT03392974 Phase 3
37 A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions Active, not recruiting NCT03370913 Phase 3
38 The Synergistic Effect of Hypoglycemic Index Diet on Refractory Schizophrenia Enrolling by invitation NCT04302636 Phase 3
39 A Phase 3b, Single Arm, Open-Label Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII, With Prophylactic Corticosteroids in Hemophilia A Patients Not yet recruiting NCT04323098 Phase 3
40 Atomized Intranasal Vs Intravenous Ketorolac in Acute Renal Colic Pain Management: A Randomized Controlled Double-blinded Clinical Trial. Not yet recruiting NCT04441762 Phase 2, Phase 3 Intravenous Ketorolac Tromethamine;Intranasal Ketorolac Tromethamine
41 Does Cleansing of Suction Blood During Cardiac Surgery With Heart and Lung Machine Reduce the Postoperative Inflammatory Response ? Terminated NCT00159926 Phase 3
42 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients With Congenital Hemophilia A With Factor VIII Inhibitors Terminated NCT01434511 Phase 3
43 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
44 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
45 Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B Withdrawn NCT02048111 Phase 3
46 Prophylactic Oxytocin Before Versus After Placental Delivery to Reduce Blood Loss in Vaginal Delivery Unknown status NCT03006380 Phase 2 oxytocin
47 A Multi-center Randomized Clinical Trial of Regulating Gut Microbiota by Probiotic Agents in Management of Immune Thrombocytopenia Unknown status NCT03033199 Phase 2 Probiotic Agent;Dexamethasone
48 Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury and Post Operative Bleeding in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Double-blind, Placebo-controlled Pilot Study Unknown status NCT02191839 Phase 1, Phase 2 Alpha 1-Antitrypsin
49 Eltrombopag for Inherited Thrombocytopenias Completed NCT02422394 Phase 2 Eltrombopag
50 Effect of Sildenafil on Digital Ulcers in Systemic Sclerosis Completed NCT00624273 Phase 2 Sildenafil therapy

Search NIH Clinical Center for Hemorrhagic Disease

Cochrane evidence based reviews: hemorrhagic disorders

Genetic Tests for Hemorrhagic Disease

Anatomical Context for Hemorrhagic Disease

MalaCards organs/tissues related to Hemorrhagic Disease:

Liver, Testes, Lung, T Cells, Colon, Endothelial, Heart

Publications for Hemorrhagic Disease

Articles related to Hemorrhagic Disease:

(show top 50) (show all 1796)
# Title Authors PMID Year
Gross hematuria due to acquired haemophilia in hereditary hemorrhagic telangiectasia. 61 54
18832920 2008
Genetic diagnosis of haemophilia and other inherited bleeding disorders. 54 61
16684001 2006
[Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases]. 61 54
16176858 2006
High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. 54 61
16091456 2005
Carrier detection and prenatal diagnosis of hemophilia in developing countries. 54 61
16276463 2005
[Coagulation disorders following severe trauma: surgeon's role in prevention]. 61 54
15605516 2004
Severe congenital factor X deficiency with intracranial bleeding in two siblings. 54 61
15036435 2004
Factor VIII inhibitor with catalytic activity towards factor VIII. 54 61
11187883 2000
[Study on genetic mutations of the vWF in type 2A von Willebrand disease]. 54 61
10932002 2000
Catalytic activity of antibodies against factor VIII in patients with hemophilia A. 61 54
10470082 1999
Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification. 54 61
9597197 1998
The role of drought as a determinant of hemorrhagic disease in the eastern United States. 61
32227543 2020
Epizootic Hemorrhagic Disease Virus and Bluetongue Virus Seroprevalence in Wild White-tailed Deer (Odocoileus virginianus) in Florida, USA. 61
32544030 2020
Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis. 61
32307298 2020
Strict assembly restriction of peptides from rabbit hemorrhagic disease virus presented by rabbit MHC class I molecule RLA-A1. 61
32522857 2020
[Acute fever with rash, necrosis, and bullae in both lower extremities in a 12-year-old girl]. 61
32571467 2020
32549575 2020
Global Risk and Elimination of Yellow Fever Epidemics. 61
31545372 2020
Type I interferon underlies severe disease associated with Junín virus infection in mice. 61
32452770 2020
Successful treatment of hepatocellular carcinoma by laparoscopic radiofrequency ablation in a patient with hemophilia A. 61
32458219 2020
An Unusual Presentation of Hemorrhagic Disease in an Infant: A Probable Case of Abetalipoproteinemia. 61
32433446 2020
Lagovirus europeus GI.2 (rabbit hemorrhagic disease virus 2) infection in captive mountain hares (Lepus timidus) in Germany. 61
32460756 2020
NF-κB and Keap1 Interaction Represses Nrf2-Mediated Antioxidant Response in Rabbit Hemorrhagic Disease Virus Infection. 61
32161178 2020
Development and optimization of a DNA-based reverse genetics systems for epizootic hemorrhagic disease virus. 61
32144546 2020
An Embryonated Egg Transmission Model for Epizootic Hemorrhagic Disease Virus. 61
32423316 2020
Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. 61
32457420 2020
Comparative Analysis of RNA Virome Composition in Rabbits and Associated Ectoparasites. 61
32188733 2020
Emerging Infectious Diseases of Rabbits. 61
32327034 2020
Interleukin-17 suppresses grass carp reovirus infection in Ctenopharyngodon idellus kidney cells by activating NF-κB signaling. 61
32287459 2020
Proteomic Profiling of Zebrafish Challenged by Spring Viremia of Carp Virus Provides Insight into Skin Antiviral Response. 61
32176570 2020
Femoral pseudotumor secondary to injury in a patient with idiopathic thrombocytopenic purpura: Case report. 61
32282742 2020
Identification of Bunyamwera and Possible Other Orthobunyavirus Infections and Disease in Cattle during a Rift Valley Fever Outbreak in Rwanda in 2018. 61
32314686 2020
[Research Progress on New Drug Therapy for Primary Immune Thrombocytopenic Purpura in Adults--Review]. 61
32319415 2020
Clinical profiles and factors associated with mortality in adults with yellow fever admitted to an intensive care unit in Minas Gerais, Brazil. 61
32004691 2020
32212569 2020
Cellular immune dysregulation in the pathogenesis of immune thrombocytopenia. 61
31977328 2020
A novel bivalent Pasteurellosis-RHD vaccine candidate adjuvanted with Montanide ISA70 protects rabbits from lethal challenge. 61
32127779 2020
A real-time reverse-transcription isothermal recombinase polymerase amplification assay for the rapid detection of genotype III grass carp (Ctenopharyngodon idella) reovirus. 61
31843672 2020
Long-term treatment with thalidomide for severe recurrent hemorrhage from intestinal angiodysplasia in Glanzmann Thrombasthenia. 61
32200672 2020
The response to re-emergence of yellow fever in Nigeria, 2017. 61
31935537 2020
Comparison of the blood parameters and histopathology between grass carp infected with a virulent and avirulent isolates of genotype II grass carp reovirus. 61
31707078 2020
Prospective Study of Epizootic Hemorrhagic Disease Virus and Bluetongue Virus Transmission in Captive Ruminants. 61
32083292 2020
Yellow fever epizootics in non-human primates, Southeast and Northeast Brazil (2017 and 2018). 61
32075684 2020
Genetic Diversity of Culicoides stellifer (Diptera: Ceratopogonidae) in the Southeastern United States Compared With Sequences From Ontario, Canada. 61
32101615 2020
Subclinical infection of captive Asian elephants (Elephas maximus) in Thailand with elephant endotheliotropic herpesvirus. 61
31784909 2020
Elephant Endotheliotropic Herpesvirus Hemorrhagic Disease in Asian Elephant Calves in Logging Camps, Myanmar. 61
31855135 2020
Imaging Ischemic and Hemorrhagic Disease of the Brain in Dogs. 61
32528985 2020
Antibodies to Epizootic Hemorrhagic Disease Virus (EHDV) in Farmed and Wild Florida White-Tailed Deer (Odocoileus virginianus). 61
31298969 2020
31403899 2020
Zebrafish prmt7 negatively regulates antiviral responses by suppressing the retinoic acid-inducible gene-I-like receptor signaling. 61
31914680 2020

Variations for Hemorrhagic Disease

Expression for Hemorrhagic Disease

Search GEO for disease gene expression data for Hemorrhagic Disease.

Pathways for Hemorrhagic Disease

Pathways related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
Show member pathways
12.72 THBD SERPINC1 F9 F8 F7 F5
Show member pathways
Show member pathways
Show member pathways
6 11.86 VWF P2RY12 GP6 GP1BA F2
Show member pathways
11.81 F9 F7 F2 F10
8 11.71 THBD SERPINE1 F3
Show member pathways
11.69 VWF GP1BA F2
10 11.41 VWF P2RY12 GP6 F2
11 10.8 F9 F7 F2 F10
12 10.75 VWF GP6 GP1BA
14 10.51 VWF GP1BA

GO Terms for Hemorrhagic Disease

Cellular components related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.32 THBD SERPINE1 SERPINC1 P2RY12 GP6 GP1BA
2 extracellular exosome GO:0070062 10.15 VWF SERPINF2 SERPINE1 SERPINC1 SERPINA1 PLAT
3 extracellular region GO:0005576 10.13 VWF SERPINF2 SERPINE1 SERPINC1 SERPINA1 PLAT
4 extracellular space GO:0005615 10.03 THBD SERPINF2 SERPINE1 SERPINC1 SERPINA1 PLAT
5 cell surface GO:0009986 9.95 THBD SERPINF2 PLAT P2RY12 GP6 GP1BA
6 endoplasmic reticulum lumen GO:0005788 9.92 SERPINC1 SERPINA1 F9 F8 F7 F5
7 blood microparticle GO:0072562 9.8 SERPINF2 SERPINC1 F2 F13A1
8 Golgi lumen GO:0005796 9.76 F9 F7 F2 F10
9 endoplasmic reticulum-Golgi intermediate compartment membrane GO:0033116 9.71 SERPINA1 F8 F5
10 COPII-coated ER to Golgi transport vesicle GO:0030134 9.7 SERPINA1 F8 F5
11 platelet alpha granule GO:0031091 9.55 VWF F5
12 intrinsic component of external side of plasma membrane GO:0031233 9.51 F3 F10
13 platelet alpha granule lumen GO:0031093 9.5 VWF SERPINF2 SERPINE1 SERPINA1 F8 F5
14 serine-type peptidase complex GO:1905286 9.43 F7 F3
15 collagen-containing extracellular matrix GO:0062023 9.36 VWF SERPINF2 SERPINE1 SERPINC1 SERPINA1 PLAT

Biological processes related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 10.03 PLAT F9 F7 F2 F11 F10
2 platelet activation GO:0030168 9.91 VWF P2RY12 GP6 GP1BA F8 F2
3 ER to Golgi vesicle-mediated transport GO:0006888 9.91 SERPINA1 F9 F8 F7 F5 F2
4 cellular protein metabolic process GO:0044267 9.9 SERPINC1 SERPINA1 F5 F2
5 positive regulation of protein kinase B signaling GO:0051897 9.87 P2RY12 F7 F3 F10
6 platelet degranulation GO:0002576 9.87 VWF SERPINF2 SERPINE1 SERPINA1 F8 F5
7 hemostasis GO:0007599 9.86 VWF THBD SERPINC1 SERPINA1 P2RY12 GP6
8 negative regulation of endopeptidase activity GO:0010951 9.85 SERPINF2 SERPINE1 SERPINC1 SERPINA1
9 negative regulation of peptidase activity GO:0010466 9.83 SERPINF2 SERPINE1 SERPINC1 SERPINA1
10 acute-phase response GO:0006953 9.8 SERPINF2 SERPINA1 F8 F2
11 COPII vesicle coating GO:0048208 9.76 SERPINA1 F8 F5
12 regulation of blood coagulation GO:0030193 9.76 SERPINC1 GP1BA F2 F11
13 negative regulation of fibrinolysis GO:0051918 9.71 THBD SERPINF2 SERPINE1 F2
14 positive regulation of blood coagulation GO:0030194 9.69 SERPINE1 F7 F2
15 blood coagulation, extrinsic pathway GO:0007598 9.65 F7 F3 F10
16 fibrinolysis GO:0042730 9.65 SERPINF2 SERPINE1 PLAT GP1BA F2
17 blood coagulation, intrinsic pathway GO:0007597 9.63 VWF GP1BA F9 F8 F2 F11
18 negative regulation of blood coagulation GO:0030195 9.62 THBD SERPINE1
19 positive regulation of positive chemotaxis GO:0050927 9.61 F7 F3
20 plasminogen activation GO:0031639 9.61 PLAT F11
21 negative regulation of platelet activation GO:0010544 9.59 THBD F2
22 negative regulation of plasminogen activation GO:0010757 9.58 SERPINF2 SERPINE1
23 blood coagulation GO:0007596 9.55 VWF THBD SERPINC1 SERPINA1 PLAT P2RY12
24 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.54 F7 F3

Molecular functions related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.85 PLAT F9 F7 F2 F11 F10
2 serine-type peptidase activity GO:0008236 9.63 PLAT F9 F7 F2 F11 F10
3 peptidase inhibitor activity GO:0030414 9.62 SERPINF2 SERPINE1 SERPINC1 SERPINA1
4 serine-type endopeptidase inhibitor activity GO:0004867 9.56 SERPINF2 SERPINE1 SERPINC1 SERPINA1
5 protease binding GO:0002020 9.43 VWF SERPINF2 SERPINE1 SERPINC1 SERPINA1 F3
6 serine-type endopeptidase activity GO:0004252 9.17 PLAT F9 F7 F3 F2 F11

Sources for Hemorrhagic Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....